Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences
Chairunnisa, Sheila
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Earth & Planetary Sciences

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Potential Probiotic Yeasts of the Pichia Genus Isolated from ‘Dadih’, a Traditional Fermented Food of West Sumatra, Indonesia Chihombori, Tatenda Calvin; Mustopa, Apon Zaenal; Astuti, Rika Indri; Mutiara, Ilma; Refli, Redoyan; Umami, Rifqiyah Nur; Fatimah; Irawan, Herman; Ekawati, Nurlaili; Trinugroho, Joko P; Akmaliyah, Rizna; Chairunnisa, Sheila; Amani, Febriyanti Nur; Manguntungi, Baso; Hertati, Ai; Mamangkey, Jendri
HAYATI Journal of Biosciences Vol. 32 No. 2 (2025): March 2025
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.32.2.320-340

Abstract

Fermented buffalo milk, known as dadih, serves as a reservoir of potential probiotic yeasts. Over the past two decades, probiotic yeasts have gained increasing attention in both basic and clinical sciences due to their health benefits. This study aimed to isolate and characterize probiotic yeasts from dadih. Yeasts were isolated using yeast Extract, peptone, and dextrose (YPD) medium, and molecularly identified through 18S-rRNA sequencing. Probiotic potential was assessed by evaluating resistance to acidic pH, bile salts, proteolytic, lipolytic, and hemolytic activities. Secondary metabolites produced during fermentation were tested for antimicrobial properties. GBT30 and GBT37 isolates were selected based on their superior performance in probiotic property assays for further analysis. Molecular identification revealed these isolates as Pichia occidentalis (GBT30) and Pichia kudriavzevii (GBT37). Both strains demonstrated in vitro survivability under simulated gastrointestinal conditions and exhibited antimicrobial activity. Whole-genome sequencing of P. kudriavzevii GBT37 identified a genome size of 10,906,850 base pairs, distributed across four chromosomes with a GC content of 38.26%. Notably, secondary metabolite biosynthesis genes were located on contig 7. In addition, 26 probiotic-related genes, including GSY1, HSC82, HSP104, TPS1, ARN1, FLO1, ALA1, SIR2, and others, were identified in P. kudriavzevii GBT37, indicating its potential as a probiotic yeast. The traditional fermentation process of dadih offers probiotic yeasts with promising health benefits, supporting its potential as a functional food.
Truncation on N-Terminal Hydrophobic Domain of L1 Major Capsid Protein of Human Papillomavirus Type 52 Enhances Its Expression in Hansenula polymorpha Arifah, Rosyida Khusniatul; Firdaus, Moh Egy Rahman; Chairunnisa, Sheila; Irawan, Shasmita; Ekawati, Nurlaili; Irawan, Herman; Nurfatwa, Maritsa; Hertati, Ai; Swasthikawati, Sri; Novianti, Ela; Mustafawi, Wike Zahra; Nur Umami, Rifqiyah; Mustopa, Apon Zaenal
HAYATI Journal of Biosciences Vol. 32 No. 4 (2025): July 2025
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.32.4.1062-1072

Abstract

Human papillomavirus (HPV) infection is the main cause of cervical cancer. The administration of the HPV prophylactic vaccine, which is commonly produced based on HPV L1 major capsid protein, significantly reduces the incidence of cervical cancer. However, the coverage of the HPV vaccination program is often hindered due to its relatively high cost. This study aimed to evaluate the impact of N-terminal hydrophobic domain truncation on the expression of L1 major capsid protein of HPV type 52 in Hansenula polymorpha. The truncation enhanced the yield of L1 protein expression compared with the full length, which was confirmed by Western blot and ELISA. Furthermore, the truncated L1 protein formed virus-like particles (VLPs), which were confirmed by transmission electron microscopy (TEM). Bioinformatics analysis showed that the truncated L1 protein was more soluble compared with the full length, possibly increasing the protein expression. These findings could pave the way for the development of a more cost-effective HPV type 52 L1 protein production in H. polymorpha to be used as a VLP-based prophylactic vaccine.
Preclinical Evaluation of HPV Type 52 L1L2 Chimeric Protein as a Cervical Cancer Vaccine Candidate Sari, Isti Kartika; Pamungkas, Joko; Mustopa, Apon Zaenal; Wibawan, I Wayan Teguh; Mamangkey, Jendri; Chairunnisa, Sheila; Irawan, Herman; Hertati, Ai; Ekawati, Nurlaili; Umami, Rifqiyah Nur; Novianti, Ela; Nurfatwa, Maritsa; Darusman, Huda Shalahudin
HAYATI Journal of Biosciences Vol. 33 No. 3 (2026): May 2026
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.33.3.556-565

Abstract

High-risk human papillomaviruses (HPVs) are the primary etiological agents of cervical cancer, accounting for more than 300,000 deaths annually worldwide. Current prophylactic vaccines based on recombinant L1 major capsid virus-like particles (VLPs) have demonstrated strong efficacy but are restricted to a limited spectrum of HPV types. To address this limitation, the present study evaluated a recombinant L1L2 chimeric protein derived from HPV type 52 as a potential candidate for a broad-spectrum vaccine. The chimeric protein was expressed in Escherichia coli strain BL21 (DE3) and purified for immunization studies. Female BALB/c mice (Mus musculus, n = 5 groups) were immunized, and immune responses were analyzed by enzyme-linked immunosorbent assay (ELISA) and pseudovirion-based neutralization assays (PBNA). The recombinant L1L2 vaccine candidate induced detectable antibody responses against HPV antigens; however, neutralizing activity remained modest. Histopathological analysis of liver and kidney tissues showed no evidence of toxicity, supporting the safety profile of the candidate. In summary, these results suggest that the HPV type 52 L1L2 chimeric protein represents a promising platform for the development of cervical cancer vaccines, although further optimization is required to achieve robust cross-neutralizing efficacy.
Co-Authors Ai Hertati, Ai Akmaliyah, Rizna Amani, Febriyanti Nur Apon Zaenal Mustopa Arifah, Rosyida Khusniatul Chihombori, Tatenda Calvin Ekawati, Nurlaili Fatimah Firdaus, Moh Egy Rahman Huda Shalahudin Darusman I wayan Teguh Wibawan Irawan, Herman Irawan, Shasmita Jendri Mamangkey Joko Pamungkas Manguntungi, Baso Mustafawi, Wike Zahra Mutiara, Ilma Novianti, Ela Nur Umami, Rifqiyah Nurfatwa, Maritsa Refli, Redoyan Rifqiyah Nur Umami, Rifqiyah Nur Rika Indri Astuti Sari, Isti Kartika Sri Swasthikawati, Sri Trinugroho, Joko P